The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMID 11289057)

Published in Diabetes on April 01, 2001

Authors

J A Douglas1, M R Erdos, R M Watanabe, A Braun, C L Johnston, P Oeth, K L Mohlke, T T Valle, C Ehnholm, T A Buchanan, R N Bergman, F S Collins, M Boehnke, J Tuomilehto

Author Affiliations

1: Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor 48109-2029, USA.

Articles citing this

Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med Genet (2008) 2.63

High-throughput screening for evidence of association by using mass spectrometry genotyping on DNA pools. Proc Natl Acad Sci U S A (2002) 2.32

Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes (2010) 2.16

Determinants of coronary artery and aortic calcification in the Old Order Amish. Circulation (2007) 2.02

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab (2007) 1.49

Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet (2005) 1.26

Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes (2007) 1.14

The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol (2008) 0.96

The association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese population. PLoS One (2013) 0.89

Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res (2009) 0.86

Variation in PPARG is associated with longitudinal change in insulin resistance in Mexican Americans at risk for type 2 diabetes. J Clin Endocrinol Metab (2015) 0.82

Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population. J Res Med Sci (2011) 0.79

Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene and strength athlete status. PLoS One (2013) 0.78

Role of peroxisome proliferator-activated receptor gamma gene polymorphisms in type 2 diabetes mellitus patients of West Bengal, India. J Diabetes Investig (2013) 0.76

Articles by these authors

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell (1992) 28.36

A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (1995) 15.20

Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol (1988) 13.73

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18

Haplotype tagging for the identification of common disease genes. Nat Genet (2001) 11.27

Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 10.90

Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res (1991) 9.56

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 9.18

Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95

Directional cloning of DNA fragments at a large distance from an initial probe: a circularization method. Proc Natl Acad Sci U S A (1984) 7.38

Quantitative estimation of insulin sensitivity. Am J Physiol (1979) 7.37

The mammalian gene collection. Science (1999) 7.19

High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation (1992) 7.11

Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet (2000) 6.94

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet (1992) 6.28

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20

Preventing non-insulin-dependent diabetes. Diabetes (1995) 6.16

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest (1981) 5.82

Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA (1999) 5.76

Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes (1993) 5.70

Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A (1999) 5.63

Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet (1997) 5.58

The molecular genetics of human hemoglobin. Prog Nucleic Acid Res Mol Biol (1984) 5.50

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ (2001) 5.40

Early growth and coronary heart disease in later life: longitudinal study. BMJ (2001) 5.25

Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia (1992) 5.25

Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ (1999) 5.17

Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. Diabetologia (1999) 5.11

How many polymorphic genes will it take to span the human genome? Am J Hum Genet (1982) 5.11

Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06

Loss of information due to ambiguous haplotyping of SNPs. Nat Genet (1999) 4.90

Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet (1999) 4.79

Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A (1990) 4.74

Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care (2000) 4.62

Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med (1990) 4.60

Improved inference of relationship for pairs of individuals. Am J Hum Genet (2000) 4.47

Estimating the power of a proposed linkage study for a complex genetic trait. Am J Hum Genet (1989) 4.42

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42

Direct sequencing of enzymatically amplified human genomic DNA. Proc Natl Acad Sci U S A (1988) 4.41

TEL1, an S. cerevisiae homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene MEC1. Cell (1995) 4.34

High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A (2001) 4.31

The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annu Rev Public Health (1985) 4.30

Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol (1996) 4.23

Assessment of insulin sensitivity in vivo. Endocr Rev (1985) 4.21

Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet (1996) 4.19

Genetic discrimination and health insurance: an urgent need for reform. Science (1995) 4.08

Change in risk factors for coronary heart disease during 10 years of a community intervention programme (North Karelia project). Br Med J (Clin Res Ed) (1983) 4.00

Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care (1998) 3.99

The genetically isolated populations of Finland and sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes. Nat Genet (2000) 3.92

Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ (1994) 3.92

Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science (1993) 3.88

Construction of a general human chromosome jumping library, with application to cystic fibrosis. Science (1987) 3.87

Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A (1997) 3.76

Two-trait-locus linkage analysis: a powerful strategy for mapping complex genetic traits. Am J Hum Genet (1993) 3.76

Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia project). Br Med J (1979) 3.75

Extensions to pedigree analysis. V. Optimal calculation of Mendelian likelihoods. Hum Hered (1983) 3.74

Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell (1990) 3.70

Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: follow up study. BMJ (1997) 3.63

Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63

Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. Lancet (1996) 3.61

Phylogenetic footprinting reveals a nuclear protein which binds to silencer sequences in the human gamma and epsilon globin genes. Mol Cell Biol (1992) 3.57

Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology (2001) 3.56

MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed (1986) 3.54

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1998) 3.41

A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia (1993) 3.35

A de novo Alu insertion results in neurofibromatosis type 1. Nature (1991) 3.29

A multipoint method for detecting genotyping errors and mutations in sibling-pair linkage data. Am J Hum Genet (2000) 3.22

Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies. Nat Genet (2001) 3.20

Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell (1999) 3.16

A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15

Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science (1991) 3.12

The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med (2000) 3.10

Extensions to pedigree analysis. IV. Covariance components models for multivariate traits. Am J Med Genet (1983) 3.10

Educational level, relative body weight, and changes in their association over 10 years: an international perspective from the WHO MONICA Project. Am J Public Health (2000) 3.08

Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A (1999) 3.07

Identifying marker typing incompatibilities in linkage analysis. Am J Hum Genet (1996) 3.06

Gestational diabetes mellitus. N Engl J Med (1999) 3.05

The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia (2009) 3.05

The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet (1995) 3.05

Symptoms of chronic bronchitis and the risk of coronary disease. Lancet (1996) 3.03

Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation (1995) 2.99

Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes (1987) 2.95

Theory and action for health promotion illustrations from the North Karelia Project. Am J Public Health (1982) 2.95

Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. Int J Epidemiol (1994) 2.91

Social class, health behaviour, and mortality among men and women in eastern Finland. BMJ (1995) 2.89

The phytopathogenic bacteria Erwinia carotovora infects Drosophila and activates an immune response. Proc Natl Acad Sci U S A (2000) 2.86

Estimating the power of a proposed linkage study: a practical computer simulation approach. Am J Hum Genet (1986) 2.84

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 2.83

Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest (1987) 2.81

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ (1995) 2.80